Date: June 16, 2026
Series: The Business of Health with Chip Kahn
Host: Charles N. “Chip” Kahn III
Guest: Dr. Alexander J. “AJ” Blood, CEO of AIwithCare
Introduction: The Bottleneck of Modern Medicine
In the rapidly evolving landscape of 21st-century medicine, the bridge between groundbreaking research and patient bedside care is often fractured by a singular, persistent bottleneck: clinical trial recruitment. For decades, the process of identifying, matching, and enrolling patients into life-saving trials has been slow, manual, and prone to systemic bias.
In the latest episode of The Business of Health, host Chip Kahn sits down with Dr. Alexander J. “AJ” Blood—a practicing cardiologist at Brigham and Women’s Hospital and the visionary co-founder of AIwithCare—to explore how artificial intelligence is not merely an auxiliary tool, but a transformative force capable of dismantling these traditional barriers. Through the lens of his startup’s proprietary tool, RECTIFIER, Dr. Blood illustrates how the integration of large-scale data analytics is redefining the efficiency of clinical research and the inclusivity of patient care.
Main Facts: The AI-Driven Shift in Clinical Operations
The core of the discussion centers on the practical application of AI in clinical settings. Historically, clinical trial recruitment has relied on physician referrals or manual chart reviews, both of which are time-consuming and often miss potential candidates.
- Scalability: AI allows for the real-time, automated scanning of vast patient databases, identifying candidates who meet highly specific inclusion and exclusion criteria in seconds.
- The RECTIFIER Innovation: Standing for RAG-Enabled Clinical Trial Infrastructure for Inclusion Exclusion Review, this tool leverages Retrieval-Augmented Generation (RAG) to sift through unstructured clinical notes, lab results, and patient histories to ensure no eligible patient is overlooked.
- Operational Efficiency: By streamlining the identification process, AI reduces the administrative burden on clinical staff, allowing them to focus on the human elements of patient care and trial management.
Chronology: The Evolution of Clinical Research Technology
To understand the significance of this technological leap, one must view the history of clinical research as a progression toward data-centricity:
- The Pre-Digital Era (Pre-2000s): Recruitment was entirely decentralized, relying on the memory and local networks of individual principal investigators.
- The Electronic Health Record (EHR) Adoption (2000s–2015): The digitization of health data provided the raw material for research but created a "data silo" problem. Data became abundant but largely inaccessible for rapid analysis.
- The Rise of Algorithmic Screening (2015–2022): Early attempts at automated screening used simple rule-based logic, which often failed to interpret the nuance of physician notes or complex medical histories.
- The Generative AI Revolution (2023–Present): With the advent of Large Language Models (LLMs) and RAG, we have entered an era where machines can "understand" the context of a medical record, enabling the precise, nuanced matching seen in platforms like AIwithCare.
Supporting Data: Why Inclusivity Matters
A significant portion of the discussion between Kahn and Dr. Blood focuses on the "representation crisis" in clinical trials. For years, trials have struggled to recruit cohorts that reflect the true demographic diversity of the patient populations they aim to treat.
- The Data Gap: Clinical trial participants have historically skewed toward certain demographics, often leaving women, minority populations, and elderly patients underrepresented. This creates "evidence gaps" where the efficacy of a drug in a diverse population remains speculative.
- AI as a Corrective Tool: AI, if programmed with an eye toward equity, can actively seek out diverse patient populations. By identifying patients across broader health systems—rather than relying on a handful of elite research centers—AI can help ensure that trial participants are a true mirror of the population affected by the condition.
- Patient Outcomes: Studies referenced by Dr. Blood indicate that when trials are more representative, the subsequent adoption of the therapy is higher, and post-market safety concerns are significantly lower, as the drug’s behavior is understood across a wider array of biological and socioeconomic profiles.
Official Perspectives and Professional Insights
The Host’s Perspective: Chip Kahn
Chip Kahn, a senior visiting fellow at KFF, emphasizes the "business of health"—the intersection where policy, finance, and patient welfare meet. From his vantage point, the adoption of AI is not just a technological choice but an economic necessity. The cost of bringing a new drug to market is soaring, with a significant percentage of those costs attributed to recruitment delays. By accelerating this phase, AI serves as a mechanism to reduce the total cost of drug development, potentially lowering the eventual price of therapies for consumers.
The Guest’s Perspective: Dr. A.J. Blood
Dr. Blood brings a unique dual perspective: that of a high-level technologist and a clinician working in the trenches of a Cardiac Surgical Intensive Care Unit. He argues that AI is not a replacement for clinical judgment but an "accelerator." He highlights that the most important aspect of AI in medicine is "trustworthiness." For AI to be useful, it must be interpretable—doctors must understand why the AI flagged a particular patient. His focus at AIwithCare is on creating "human-in-the-loop" systems where the AI provides the data, but the physician maintains the ultimate clinical authority.
Implications: The Future of Health Care
The integration of tools like RECTIFIER into the standard clinical workflow signals a profound shift in how we approach disease management.
1. Shift Toward Precision Medicine
The ability to quickly identify the right patient for the right trial means that we are moving closer to true precision medicine. Rare diseases, which were once nearly impossible to study due to the difficulty of finding patients, may see a renaissance in research as AI makes it easier to locate dispersed populations.
2. Regulatory and Ethical Challenges
As AI takes on a larger role in clinical decision-making, the regulatory environment must keep pace. The FDA and other global health bodies are currently grappling with how to validate AI tools that "learn" over time. Ensuring that these algorithms are not inheriting or amplifying historical biases is a major ethical hurdle that requires ongoing vigilance and rigorous audit trails.
3. The Changing Role of the Clinician
The physician of the future will need to be a "data-literate" practitioner. As tools like those developed by Dr. Blood become ubiquitous, the value of the clinician will shift from the manual retrieval of information to the synthesis of AI-provided insights. The doctor remains the anchor, ensuring that the technology serves the patient’s best interest.
Conclusion: A New Era of Accessibility
The conversation between Chip Kahn and Dr. A.J. Blood underscores a critical point: the future of medicine is not about machines replacing people, but about technology empowering them to do more. By solving the recruitment crisis through intelligent, data-driven infrastructure, we are not just speeding up drug discovery—we are making healthcare more inclusive, more efficient, and more effective.
As the AI series on The Business of Health continues, it becomes clear that the tools being built today are the foundation of tomorrow’s medical breakthroughs. With leaders like Dr. Blood steering the ship, the integration of artificial intelligence into clinical research is not just a trend; it is the necessary next step in our pursuit of universal, equitable health outcomes.
For more information on the evolving role of AI in healthcare, listeners are encouraged to visit the KFF Business of Health series page to access full podcast episodes, transcripts, and supplementary materials on the intersection of technology, policy, and patient care.
About the Author
